My personal opinion is based on the studies, research reports, and journal submissions that say the covid vaccines offer protection from the effects of the virus:
April 21, 2022 https://www.nejm.org/doi/full/10.1056/NEJMoa2119451 "Primary immunization with two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccine provided limited protection against symptomatic disease caused by the omicron variant. A BNT162b2 or mRNA-1273 booster after either the ChAdOx1 nCoV-19 or BNT162b2 primary course substantially increased protection"
07 May 2022 https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-022-07418-y "VE against SARS-CoV-2 infection and symptomatic COVID-19 waned over time but protection remained high against severe COVID-19. These data can be used to inform public health decisions around the need for booster vaccination."
My personal opinion is based on the studies, research reports, and journal submissions that say the covid vaccines offer protection from the effects of the virus:
April 11, 2022 https://publichealth.jhu.edu/2022/an-update-on-covid-vaccines "The more vaccines we have that people are willing to take, the better off we're going to be."
May 5, 2022 https://www.mayoclinic.org/coronavirus-covid-19/covid-variant-vaccine "the COVID-19 vaccines are effective at preventing severe illness."
April 21, 2022 https://www.nejm.org/doi/full/10.1056/NEJMoa2119451 "Primary immunization with two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccine provided limited protection against symptomatic disease caused by the omicron variant. A BNT162b2 or mRNA-1273 booster after either the ChAdOx1 nCoV-19 or BNT162b2 primary course substantially increased protection"
07 May 2022 https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-022-07418-y "VE against SARS-CoV-2 infection and symptomatic COVID-19 waned over time but protection remained high against severe COVID-19. These data can be used to inform public health decisions around the need for booster vaccination."